Research Topics
| Nicholas ButowskiSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)Nicholas Butowski
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0350, USA
J Neurooncol 91:175-82. 2009....- Endpoints for clinical trials and revised assessment in neuro-oncologyNicholas Butowski
Division of Neuro Oncology, Department of Neurological Surgery, University of California San Francisco, San Francisco, California 94143 0350, USA
Curr Opin Neurol 25:780-5. 2012..However, inadequacies of clinical trial endpoints have challenged how best to evaluate promising new therapeutics... - Medical management of brain metastasesNicholas Butowski
Department of Neurological Surgery, University of California, 400 Parnassus Avenue 0372, San Francisco, CA 94143, USA
Neurosurg Clin N Am 22:27-36, v-vi. 2011..Radiation therapy and surgery are discussed in detail elsewhere; however, a brief discussion of all of these modalities is included for the sake of thoroughness... 
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I studyNicholas Butowski
Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
Neuro Oncol 12:608-13. 2010..The proceeding phase II trial has finished accrual and results will be reported in 2009...- Immunostimulants for malignant gliomasNicholas Butowski
Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143, USA
Neurosurg Clin N Am 21:53-65. 2010..Combining these strategies with more than one mode of immunotherapy may provide better clinical results... - A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomasNicholas Butowski
Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143 0350, USA
J Neurooncol 91:183-9. 2009..Based on this study, poly-ICLC does not improve 6moPFS in patients with recurrent anaplastic gliomas but may be worth further study in combination with agents such as temozolomide... - Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcomaNicholas Butowski
Neuro Oncology Service, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
Neuro Oncol 13:1331-8. 2011..Adjusting for age and KPS, no other biomarker was associated with survival outcome. Correlation of relevant biomarkers with OS may be useful in future trials... 
Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiformeNicholas Butowski
Neuro Oncology Service, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
J Neurooncol 85:87-94. 2007..Patients treated during surgically based phase II studies should be matched with a historical control group restricted to patients with similar pretreatment variables, including GTR...- Anti-angiogenic therapy in gliomaNicholas Butowski
Department of Neuro Oncology, Brain Tumor Research Center, University of California, San Francisco, CA 94143 0350, USA
Clin Transl Oncol 13:294-300. 2011..This manuscript reviews the landscape of anti-angiogenic therapy in glioma, with a focus on GBM, and demonstrates that further innovation is needed to determine the true utility of anti-angiogenic therapy... - Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcomaMichael D Prados
University of California, San Francisco, CA 94143, USA
J Clin Oncol 27:579-84. 2009..The objectives were to determine efficacy of this treatment as measured by survival and to explore the relationship between molecular markers and treatment response... - A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastomaNicholas Butowski
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
Int J Radiat Oncol Biol Phys 61:1454-9. 2005..Based on this study, cRA does not seem to add a significant synergistic effect to TMZ and XRT... - Identifying the needs of brain tumor patients and their caregiversRupa Parvataneni
Division of Neuro Oncology in the Department of Neurosurgery, University of California, San Francisco, CA 94143, USA
J Neurooncol 104:737-44. 2011.... - Quality of life in low-grade glioma patients receiving temozolomideRaymond Liu
Department of Medicine, Division of Hematology Oncology Neuro Oncology, University of California, San Francisco, CA 94143 2167, USA
Neuro Oncol 11:59-68. 2009..While remaining on therapy, LGG patients were able to maintain their QOL in all realms. LGG patients' QOL may be further improved by addressing their emotional well-being and their loss of independence in terms of driving or working... - Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant gliomaMichael D Prados
Department of Neurosurgery, University of California, San Francisco, CA 94143 0372, USA
Neuro Oncol 8:67-78. 2006..There was a modest pharmacokinetic interaction between erlotinib and temozolomide. The favorable tolerability profile and evidence of antitumor activity indicate that further investigation of erlotinib is warranted... - Preoperative prognostic classification system for hemispheric low-grade gliomas in adultsEdward F Chang
Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, California 94143, USA
J Neurosurg 109:817-24. 2008..As a result, the objective in the present study was to design a preoperative scoring system to prognosticate long-term outcomes in patients with LGGs... - Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomideMei Yin C Polley
Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, Room A 808, Box 0372, San Francisco, California 94143 2167, USA
Neuro Oncol 12:274-82. 2010..Our analysis suggests that 6-month PFS may be an appropriate primary endpoint in the context of phase II upfront GBM trials in the TMZ era... - Recent advances in therapy for glioblastomaJennifer Clarke
Division of Neuro Oncology, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Ave, Room A 808, Box 0372, San Francisco, CA 94143 0372, USA
Arch Neurol 67:279-83. 2010.... - Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapyAshley H Aiken
Department of Radiology, University of California San Francisco, San Francisco, CA, USA
Int J Radiat Oncol Biol Phys 72:1340-6. 2008..To compare temporal patterns of recurrent contrast enhancement in patients with glioblastoma multiforme (GBM) treated with brachytherapy plus external beam radiotherapy (EBRT) vs. EBRT alone... - Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed gliomaSusan M Chang
Department of Neurological Surgery, UCSF, 505 Parnassus Ave, San Francisco, CA 94143, USA
J Neurooncol 92:401-15. 2009.... - Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone proteinCourtney A Crane
Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94141, USA
Clin Cancer Res 19:205-14. 2013..Here we show that peptides bound to a 96 kD chaperone protein (HSP-96) from brain tissue containing glioblastoma multiforme (GBM) can be used to safely immunize patients with recurrent GBM... - Small molecule and monoclonal antibody therapies in neurooncologyNicholas Butowski
Department of Neurological Surgery, University of California, San Francisco, CA 94143-0350, USA
Cancer Control 12:116-24. 2005..Further study of these agents in well-designed cooperative clinical trials is needed... - Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenograftsPin Yuan Chen
Department of Neurological Surgery, University of California San Francisco, 1450 Third Street, Room HD 283, San Francisco, CA 94158, USA
Neuro Oncol 15:189-97. 2013.... - GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trialsSusan M Chang
Department of Neurological Surgery, University of California, San Francisco, CA 94143, USA
Neuro Oncol 7:425-34. 2005..Our guidelines are summarized in a checklist format that can be used as a framework from which to construct a phase 1 or 2 clinical trial... - Therapeutic advances for glioblastoma multiforme: current status and future prospectsH Ian Robins
University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA
Curr Oncol Rep 9:66-70. 2007..We anticipate that a multimodality approach directed at tumor-specific biology will result in more meaningful advancements in the treatment of this fatal disease...